Results 141 to 150 of about 8,114 (214)

Temporal dynamics of IgG-mediated immunometabolic dysfunction: from acute obesity to chronic aging. [PDF]

Front Immunol
Kim S, Kim J, Lee HL, Kim MS.
europepmc   +1 more source

Efgartigimod for Generalized Myasthenia Gravis and Beyond: A Narrative Review of Its Pharmacological Profile, Clinical Utility, and Expanding Applications. [PDF]

Biomedicines
Mansour GK, Alangari L, Khosyfan L, Alhammad R, Hajjar AW.   +4 more
europepmc   +1 more source

Immunoglobulin G Fc engineering for localized therapy: Eliminating neonatal Fc receptor interactions and ensuring purification using protein A. [PDF]

Protein Sci
Kato A, Toshima A, Takekawa G, Miyagi H, Kubota A, Hori S, Uemura Y, Niwa R.   +7 more
europepmc   +1 more source

Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro [PDF]

Omar Qureshi, Emma J. Sutton, Rosemary F. Bithell, Shauna West, Rona M. Cutler, Gillian McCluskey, Graham Craggs, Asher Maroof, Nicholas M. Barnes, David P. Humphreys, Stephen Rapecki, Bryan John Smith, Anthony Shock   +12 more
openalex   +1 more source

Immunotherapy in Chronic Inflammatory Demyelinating Polyneuropathy and the Emerging Role of Efgartigimod. [PDF]

J Clin Neurol
Park JS, Kang M.
europepmc   +1 more source

OP0041 Treatment of primary Sjögren's disease by blocking FcRn: clinical and translational data from RHO, a phase 2 randomized, placebo controlled, double-blind, proof-of-concept study with efgartigimod

Isabelle Peene, Gwenny M. Verstappen, Joke Deprez, Frans G. M. Kroese, S. Arends, Aaron S. Kelly, L. Vandersarren, E Frances Bowen, Johannes W. G. Jacobs, Paul Meyvisch, Dirk Elewaut, Hendrika Bootsma   +11 more
openalex   +1 more source

“Single molecule tracking unveils distinct FcγRIIB and FcRn plasma membrane dynamics”

Marta Rojas‐Rodríguez, Francesco S. Pavone, Martino Calamai   +2 more
openalex   +1 more source

Tumor intrinsic properties dictate Fc receptor expression and cancer cachexia associated increase in checkpoint inhibitor clearance. [PDF]

Front Immunol
Remaily BC, Young G, Lathrop H, Thomas J, Kim K, Vu TT, Adeluola A, Stanton C, Mulcahy G, Xie Z, Granchie L, Guo Y, Hai M, Wedig J, Schmidt M, Manna M, Mo X, Lowe J, Rafael-Fortney JA, Folefac E, Gregorevic P, Owen DH, Kulp SK, Ganesan LP, Coss CC, Mace TA, Phelps MA.   +26 more
europepmc   +1 more source

Table 2_Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network.docx

Luqiong Wang (22389295), Jiaojiao Chen (6711764), Huixiang Li (280714), Lin Wang (11986), Feiyu Liu (18291112), Xiaoli Jiang (418410)   +5 more
openalex   +1 more source

Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn [PDF]

, 2009
Hai Pan, Kenneth Chen, Liping Chu, Francis Kinderman, Izydor Apostoł, Gang Huang   +5 more
openalex   +1 more source